USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Discovery of New Targeted Therapies Will Replace Conventional Therapies
This study assesses marketed and in-research products and combination regimens for the lung cancer therapeutics market. Segmentation by drug class is provided, along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented by their mechanism of action against cancer. Cost-effective treatments and targeted therapies are the key unmet needs of the market.
Executive Summary
Executive Summary (continued)
Executive Summary (continued)
Methodology and Scope
Market Overview—Segmentation
Market Overview—Segmentation (continued)
Market Overview—Segmentation (continued)
Recent Market Developments
Companies to Watch
Key Merger, Acquisition, and Partnership Assessment
Game-changing Strategies
Epidemiology
Epidemiology (continued)
Epidemiology (continued)
Competitive Landscape—Marketed and Pipeline Drugs in Pre-registration and Phase 3
Competitive Landscape—Pipeline Drugs in Phase 1 and Phase 2
Timeline of Product Launches/Approval
Timeline of Patent Expiries
Competitive Landscape—Pivotal Clinical Trials
Competitive Landscape—Pivotal Clinical Trials (continued)
Marketed Products Synopsis
Marketed Products Synopsis (continued)
Marketed Products Synopsis (continued)
Marketed Products Synopsis (continued)
Pipeline Synopsis
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Product Dashboard: Tarceva® (Erlotinib)—Roche Group
Product Dashboard: Gilotrif® (Afatinib)—Boehringer Ingelheim
Product Dashboard: Avastin® (Bevacizumab)—Genentech Inc. (Roche Group)
Product Dashboard: Alimta® (Pemetrexed)—Eli Lilly and Company
Product Dashboard: XALKORI® (Crizotinib)—Pfizer Inc.
Product Dashboard: AP26113—Ariad Pharmaceuticals, Inc.
Product Dashboard: Necitumumab—Eli Lilly and Company
Product Dashboard: Nivolumab—Bristol-Myers Squibb Company and Ono Pharmaceutical
Conclusions
Legal Disclaimer
About Lung Cancer
About Lung Cancer (continued)
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related industry research
16 Sep 2026 | North America | Customer Research
US Automotive Technicians’ Choice Survey, 2025
The 2025 US Automotive Technicians’ Choice study is an insightful voice-of-customer survey that highlights the tool preferences of automotive aftermarket service technicians. The survey of 400 automotive technicians across the United States used a combination of computer-assisted telephone and compu...
16 Sep 2026 | Global | Market Research
Apple Performance Tracker, Q1 2026
This Frost & Sullivan tracker provides metrics on Apple's quarterly performance (for both unit sales and revenues) for iPads, iPhones, Macs, and other products, such as iPods, Apple TVs, Beats Electronics, and Apple-branded and third-party accessories. It includes historical quarterly data for all t...
15 Sep 2026 | Global | Technology Research
Growth Opportunities in Workload Identity and Access Management, Non-Human Identity Security, Threat Exposure Management, and Blockchain Security
This edition of the Cyber Security Technology Opportunity Engine (TOE) showcases emerging cybersecurity innovators advancing AI-powered security, identity and access management, data security, threat exposure management, blockchain security, cyber incident response, network protection, and agentic A...
15 Sep 2026 | South Asia, Middle East & North Africa | Market Research
Future of Growth and Emerging Opportunities in the Gulf Cooperation Council, 2025–2030
The GCC has entered a period of strategic economic transformation as governments accelerate diversification efforts, strengthen economic resilience, and reduce dependence on hydrocarbon revenue amid heightened geopolitical uncertainty and evolving global trade dynamics. While the implications of the...
15 Sep 2026 | Global | Market Research
Vendor Profiles: Advanced Wound Care Management Market, Global, 2025
The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Sumedha Pareek |
| WIP Number | MAC3-01-00-00-00 |
| Is Prebook | No |
A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market
$3,950.00
Special Price $2,962.50 save 25 %